Erste Asset Management GmbH Acquires Shares of 7,200 Nkarta, Inc. (NASDAQ:NKTX)

Erste Asset Management GmbH bought a new position in shares of Nkarta, Inc. (NASDAQ:NKTX) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 7,200 shares of the company’s stock, valued at approximately $33,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Meeder Asset Management Inc. purchased a new stake in Nkarta in the 2nd quarter worth $26,000. GAMMA Investing LLC lifted its position in shares of Nkarta by 1,887.0% in the second quarter. GAMMA Investing LLC now owns 4,729 shares of the company’s stock worth $28,000 after buying an additional 4,491 shares in the last quarter. Forefront Analytics LLC bought a new position in Nkarta during the second quarter valued at approximately $70,000. Intech Investment Management LLC purchased a new position in Nkarta during the 3rd quarter valued at approximately $74,000. Finally, SG Americas Securities LLC bought a new stake in Nkarta in the 3rd quarter worth approximately $93,000. Institutional investors own 80.54% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. RODMAN&RENSHAW raised Nkarta to a “strong-buy” rating in a research note on Wednesday, October 9th. Needham & Company LLC decreased their price target on shares of Nkarta from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. HC Wainwright decreased their price target on shares of Nkarta from $22.00 to $18.00 and set a “buy” rating on the stock in a research note on Monday, November 11th. Mizuho decreased their price target on shares of Nkarta from $20.00 to $16.00 and set an “outperform” rating on the stock in a research note on Thursday, November 21st. Finally, Rodman & Renshaw started coverage on shares of Nkarta in a research note on Wednesday, October 9th. They set a “buy” rating and a $14.00 price target on the stock. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Nkarta currently has a consensus rating of “Buy” and a consensus price target of $15.00.

Nkarta Trading Up 0.7 %

Shares of NKTX opened at $2.72 on Thursday. Nkarta, Inc. has a twelve month low of $2.38 and a twelve month high of $16.24. The company has a market cap of $191.95 million, a P/E ratio of -1.45 and a beta of 0.82. The company’s fifty day simple moving average is $3.42 and its 200-day simple moving average is $5.03.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.